



CHIA TAI ENTERPRISES INTERNATIONAL LIMITED
正大企業國際有限公司

Incorporated in Bermuda with members' limited liability • Stock Code : 3839
於百慕達註冊成立之成員有限責任公司 • 股份代號 : 3839

INTERIM REPORT 2023 中期報告

Contents

目錄

- 2 Management Discussion and Analysis
管理層討論及分析
- 6 Report on Review of Interim Financial Report
中期財務報告之審閱報告
- 8 Consolidated Statement of Comprehensive Income
綜合全面收益表
- 10 Consolidated Statement of Financial Position
綜合財務狀況表
- 12 Consolidated Statement of Changes in Equity
綜合權益變動表
- 14 Condensed Consolidated Statement of Cash Flows
簡明綜合現金流量表
- 15 Notes to Interim Financial Report
中期財務報告附註
- 31 Other Information
其他資料
- 35 Corporate Information
公司資料

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

GROUP RESULTS

The Group has two lines of business: biochemical business and industrial business. The biochemical business focuses on chlortetracycline (“CTC”) and other related products, and is carried on by Group subsidiaries. This business segment accounts for all of the Group’s consolidated revenue. The industrial business comprises the Group’s interests in its joint venture ECI Metro Investment Co., Ltd. (together with its subsidiaries, “ECI Metro”) and its associate Zhanjiang Deni Vehicle Parts Co., Ltd. (together with its subsidiaries, “Zhanjiang Deni”). The results of the Group’s industrial business are incorporated in the consolidated statement of comprehensive income as share of profits and losses of joint venture and associate.

For the six months ended 30 June 2023 (“1H23”), the Group’s revenue increased by 2.0% to US\$82.81 million. For the six months ended 30 June 2022 (“1H22”), the Group’s revenue was US\$81.21 million. Overall gross profit margin was at 22.3% (1H22: 23.6%).

Profit attributable to shareholders of the Company was US\$2.03 million (1H22: loss of US\$4.98 million). The turn from loss to profit was mainly due to improved performance of our industrial business. Share of profits and losses of ECI Metro improved from a loss of US\$5.34 million in 1H22 to a profit of US\$2.61 million in 1H23.

Basic and diluted profit per share were both 0.80 US cents (1H2022: loss of 1.97 US cents). The board of directors of the Company resolved not to declare an interim dividend for the six months ended 30 June 2023 (1H22: Nil).

BUSINESS REVIEW

Biochemical

We generate a sizable portion of our revenue from the manufacture and sale of CTC products (CTC Premix and CTC HCL) and animal health products. CTC products are antibiotics used to prevent or cure animal diseases. While our animal health products are mainly preventive drugs for livestock diseases. In the past few years, we have been strategically broadening our product portfolio to cover other related veterinary products. Of these new offerings, some we manufacture and sale, and some we source and trade. The Group’s major customers include farms, pharmaceutical companies, trading companies and feed mills.

集團業績

本集團從事生化業務及工業業務。生化業務專注於金霉素及其他相關產品，並由本集團之附屬公司營運，乃佔本集團的所有綜合收入。工業業務包含本集團於ECI Metro Investment Co., Ltd. (及其附屬公司，統稱「ECI Metro」) 的合營企業權益及於湛江德利車輛部件有限公司 (及其附屬公司，統稱「湛江德利」) 的聯營公司權益。本集團工業業務的業績載列於綜合全面收益表內的應佔合營企業及聯營公司溢利及虧損。

截至二零二三年六月三十日止六個月 (「二零二三年上半年」)，本集團的收入上升2.0%至8,281萬美元。截至二零二二年六月三十日止六個月 (「二零二二年上半年」)，本集團的收入為8,121萬美元。整體毛利率為22.3% (二零二二年上半年：23.6%)。

本公司股東應佔溢利為203萬美元 (二零二二年上半年：虧損498萬美元)。由虧轉盈主要由於工業業務表現有改善，應佔ECI Metro溢利及虧損從二零二二年上半年虧損534萬美元改善至二零二三年上半年盈利261萬美元。

每股基本及攤薄溢利為0.80美仙 (二零二二年上半年：虧損1.97美仙)。本公司董事會決議截至二零二三年六月三十日止六個月不派付中期股息 (二零二二年上半年：無)。

業務回顧

生化業務

我們的收入大部分來自製造及銷售金霉素產品 (金霉素預混劑及鹽酸金霉素) 和動保化藥產品。金霉素產品為用作預防或治療動物疾病的抗生素。而我們的動保化藥產品主要是用作家畜疾病的防治藥。近年，我們一直在戰略性地擴大我們的產品組合，以涵蓋其他相關的獸藥產品。在這些新產品中，一部分我們製造及銷售，一部分我們採購和貿易。本集團的主要客戶包括養殖場、製藥公司、貿易公司及飼料加工廠。

In 1H23, the Group's revenue from the biochemical business amounted to US\$82.81 million (1H22: US\$81.21 million). While sales remained stable, our sales mix changed in line with our strategic business direction. Revenue contribution from CTC products decreased from 57% in 1H22 to 48% in 1H23, while revenue contribution from animal health products, trading and other segments increased from 43% in 1H22 to 52% in 1H23. Gross profit margin in 1H23 was 22.3% (1H22: 23.6%).

Due to reduced CTC product demand in 1H23, our factory utilisation rate dropped, increasing our production overhead in this period. Again, in line with our strategic business direction, we continued to deploy additional marketing efforts to expand our animal health and trading businesses. Overall, contribution from our biochemical business declined in 1H23.

Industrial

The Group's industrial business is conducted through ECI Metro and Zhanjiang Deni.

ECI Metro is principally engaged in the sale, leasing and servicing of Caterpillar machinery equipment in western China. The excavator market in China had been impacted by a decline in construction machinery demand since 2022. According to the China Construction Machinery Association, excavator sales across the entire market in 1H2023 was 43.8% lower than that in 1H2022. Our market share in the small and medium-sized construction machinery segment was also continuously challenged by domestic brands in China. Nevertheless, revenue and gross profit from sales of spare parts and services increased due to rising demand. Furthermore, machinery with new emission standards had better gross profit margin. As a result, for the six months ended 30 June 2023, our share of profits and losses of joint venture improved from a loss of US\$5.34 million in 1H22 to a profit of US\$2.61 million in 1H23.

Zhanjiang Deni is principally engaged in the manufacture and sale of automotive parts, which are mainly sold to automobile and motorcycle manufacturers. According to the China Association of Automobile Manufacturers, automobile sales in 1H2023 increased by 9.8% when compared to 1H2022. On the other hand, according to China Chamber of Commerce for Motorcycle, China motorcycle sales in 1H2023 was 10.3% lower than that in 1H2022. For the six months ended 30 June 2023, our share of profit of associate was US\$1.04 million (1H22: US\$1.11 million).

二零二三年上半年，本集團生化業務的收入為8,281萬美元（二零二二年上半年：8,121萬美元）。在銷售保持穩定的同時，我們的銷售結構隨著我們的戰略業務方向發生了變化。金霉素產品的收入佔比從二零二二年上半年的57%下降至二零二三年上半年的48%，而動保化藥產品、貿易和其他部分的收入佔比從二零二二年上半年的43%增加至二零二三年上半年的52%。二零二三年上半年的毛利率為22.3%（二零二二年上半年：23.6%）。

由於金霉素產品的需求於二零二三年上半年減少，我們的工廠使用率下降，增加了我們在此期間的生產間接成本。再者，隨著我們的戰略業務方向，我們繼續部署額外的營銷工作以擴大我們的動保化藥和貿易業務。總體而言，我們的生化業務貢獻在二零二三年上半年有所下降。

工業業務

本集團的工業業務透過ECI Metro及湛江德利經營。

ECI Metro主要在中國西部從事卡特彼勒機械設備的銷售、租賃及維修服務。自二零二二年，中國挖掘機市場受工程機械需求下滑。據中國工程機械工業協會統計，二零二三年上半年挖掘機總體市場銷量比二零二二上半年下降43.8%。中小型工程機械的市場份額也不斷受到國內品牌生產商的挑戰。然而，銷售零件及維修服務的收入和毛利因需求上升而增加。此外，符合新排放標準的機械有較好毛利率。因此，截至二零二三年六月三十日止六個月，應佔合營企業溢利及虧損從二零二二上半年的虧損534萬美元改善至二零二三年上半年的溢利261萬美元。

湛江德利專注製造及銷售汽車零件，主要出售予汽車及摩托車製造商。根據中國汽車工業協會統計，二零二三年上半年汽車銷售量比二零二二上半年增加9.8%，而根據中國摩托車商會統計，中國摩托車二零二三年上半年銷售量則較二零二二上半年下降10.3%。截止二零二三年六月三十日止六個月，應佔聯營公司溢利為104萬美元（二零二二年上半年：111萬美元）。

OUTLOOK

Looking forward, the pace of economic recovery and intensified competition are expected to bring uncertainties to our biochemical business. For our industrial business, fixed-asset investment growth in the remainder of 2023 is expected to hover at a low level and competition is likely to remain intense. Overall, we remain cautious for our performance in the remainder of 2023.

LIQUIDITY AND FINANCIAL RESOURCES

As at 30 June 2023, the Group had total assets of US\$346.5 million, an decrease of 1.2% as compared to US\$350.6 million as at 31 December 2022.

Net debt (30 June 2023: US\$22.7 million, 31 December 2022: US\$18.2 million) to equity ratio (defined as total bank borrowings minus cash divided by total equity) was 0.09 as compared to 0.07 as at 31 December 2022.

All the borrowings of the Group were denominated in Renminbi (“RMB”) as at 30 June 2023 and 31 December 2022.

As at 30 June 2023, the Group’s fixed interest rate bank borrowings amounted to US\$28.5 million (31 December 2022: US\$26.8 million).

All domestic sales in mainland China are transacted in RMB and export sales are transacted in foreign currencies. The Group monitors exchange rate movements and determines appropriate hedging activities when necessary.

CAPITAL STRUCTURE

The Group finances its working capital requirements through a combination of funds generated from operations and borrowings. The Group had cash and cash equivalents of US\$36.2 million as at 30 June 2023, increase of US\$5.4 million compared to US\$30.9 million as at 31 December 2022.

CHARGES ON GROUP ASSETS

As at 30 June 2023, out of the total borrowings of US\$58.9 million (31 December 2022: US\$49.1 million) obtained by the Group, US\$15.0 million (31 December 2022: US\$18.3 million) was secured and accounted for 25.5% (31 December 2022: 37.3%) of the total borrowings. Certain of the Group’s property, plant and equipment and land lease prepayments with an aggregate net book value of US\$30.2 million (31 December 2022: US\$13.8 million) were pledged as security.

展望

展望未來，經濟復蘇的步伐和競爭加劇預計會為我們的生化業務帶來不確定性。至於我們的工業業務，預計今年餘下時間固定資產投資增速將徘徊在低位，而行業競爭可能仍然激烈。總體而言，我們對二零二三年餘下時間的表現保持謹慎態度。

資金流動性及財政資源

於二零二三年六月三十日，本集團之總資產為3,47億美元，較二零二二年十二月三十一日之3.51億美元，減少1.2%。

淨債務（二零二三年六月三十日：2,270萬美元，二零二二年十二月三十一日：1,820萬美元）對權益比率（定義為銀行借款減現金後除以權益總額）為0.09，相對二零二二年十二月三十一日之0.07。

本集團於二零二三年六月三十日及二零二二年十二月三十一日的借款全部按人民幣作為單位。

於二零二三年六月三十日，本集團按固定利率計息之借款為2,850萬美元（二零二二年十二月三十一日：2,680萬美元）。

於中國大陸所有國內銷售均以人民幣計算，而出口之銷售則以外幣計算。本集團監控外匯變動，必要時考慮適當的對沖活動。

資本結構

本集團透過營運資金及借款應付其流動資金需求。於二零二三年六月三十日，本集團持有現金及現金等價物3,620萬美元（二零二二年十二月三十一日：3,090萬美元），增加540萬美元。

本集團資產抵押

於二零二三年六月三十日，本集團總借款為5,890萬美元（二零二二年十二月三十一日：4,910萬美元），其中1,500萬美元（二零二二年十二月三十一日：1,830萬美元）借款需提供資產抵押，佔借款總額之25.5%（二零二二年十二月三十一日：37.3%）。本集團若干物業、廠房及設備及預付土地租賃費已用作抵押，賬面淨額合共3,020萬美元（二零二二年十二月三十一日：1,380萬美元）。

CONTINGENT LIABILITIES

As at 30 June 2023, the Group did not have any significant contingent liabilities.

SIGNIFICANT INVESTMENTS HELD, MATERIAL ACQUISITIONS AND DISPOSALS

Save for those disclosed in this interim report, there were no other significant investments held nor material acquisitions or disposals during the period.

EMPLOYEE AND REMUNERATION POLICIES

As at 30 June 2023, the Group employed around 1,000 employees in the Mainland China and Hong Kong. The Group remunerates its employees based on their performance, experience and prevailing market conditions while performance bonuses are granted on a discretionary basis. Other employee benefits include, for example, medical insurance and training.

或有負債

本集團於二零二三年六月三十日並沒有任何重大或有負債。

持有的重大投資、重大收購及出售

除本中期報告所披露外，本集團在期內沒有持有任何其他重大投資，亦沒有進行任何重大收購或出售。

僱員及酬金政策

於二零二三年六月三十日，本集團於中國大陸及香港共聘用約1,000名僱員。本集團根據僱員的表現、經驗及現行的市場水平，釐訂其薪津，並酌情授予花紅。其他僱員福利包括例如：醫療保險及培訓。

REPORT ON REVIEW OF INTERIM FINANCIAL REPORT



Review report to the board of directors of
Chia Tai Enterprises International Limited
(Incorporated in Bermuda with limited liability)

Introduction

We have reviewed the interim financial report set out on pages 8 to 30 which comprises the consolidated statement of financial position of Chia Tai Enterprises International Limited (the “Company”) and its subsidiaries (together, the “Group”) as of 30 June 2023 and the related consolidated statement of comprehensive income, consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six month period then ended and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of an interim financial report to be in compliance with the relevant provisions thereof and International Accounting Standard 34, *Interim Financial Reporting*, issued by the International Accounting Standards Board. The directors are responsible for the presentation of the interim financial report in accordance with International Accounting Standard 34.

Our responsibility is to form a conclusion, based on our review, on the interim financial report and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Scope of review

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*, issued by the Hong Kong Institute of Certified Public Accountants. A review of the interim financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

中期財務報告之審閱報告

致正大企業國際有限公司董事會之審閱報告

(於百慕達註冊成立之有限公司)

緒言

我們已審閱第8至30頁所載之中期財務報告，當中包括正大企業國際有限公司（「貴公司」）及其附屬公司（以下統稱「貴集團」）於二零二三年六月三十日的綜合財務狀況表與截至該日止六個月期間的相關綜合全面收益表、綜合權益變動表和簡明綜合現金流量表及附註解釋。香港聯合交易所有限公司證券上市規則規定，中期財務報告之編製必須符合當中有關條文，以及由國際會計準則委員會頒佈的國際會計準則第34號*中期財務報告*。董事須負責根據國際會計準則第34號編制及呈報中期財務報告。

我們的責任是根據我們的審閱對中期財務報告作出結論，並按照我們雙方所協定之委聘條款僅向全體董事會報告，且不可作其他用途。我們不會就本報告的內容，對任何其他人士負責或承擔任何責任。

審閱範圍

我們已根據香港會計師公會頒佈的香港審閱工作準則第2410號*獨立核數師對中期財務信息的審閱*進行審閱。審閱中期財務報告包括向主要負責財務和會計事務之人員作出查詢，並應用分析性和其他審閱程序。由於審閱範圍遠少於根據香港審核準則進行審核之範圍，故不能保證我們會知悉在審核中可能發現之所有重大事項。因此，我們不會發表審核意見。

**REPORT ON REVIEW OF INTERIM
FINANCIAL REPORT (CONTINUED)**

中期財務報告之審閱報告(續)

Conclusion

結論

Based on our review, nothing has come to our attention that causes us to believe that the interim financial report as at 30 June 2023 is not prepared, in all material respects, in accordance with International Accounting Standard 34, *Interim Financial Reporting*.

根據我們的審閱，我們並無發現任何事項令我們相信截至二零二三年六月三十日之中期財務報告在各重大方面未有根據國際會計準則第34號中期財務報告編製。

KPMG

Certified Public Accountants
8th Floor, Prince's Building
10 Chater Road
Central, Hong Kong

畢馬威會計師事務所

執業會計師
香港中環
遮打道10號
太子大廈8樓

10 August 2023

二零二三年八月十日

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

綜合全面收益表

		Six months ended 30 June 截至六月三十日止六個月	
		2023 二零二三年	2022 二零二二年
		US\$'000 美元千元	US\$'000 美元千元
		(Unaudited) (未經審核)	(Unaudited) (未經審核)
	Note 附註		
REVENUE	收入	82,810	81,211
Cost of sales	銷售成本	(64,401)	(62,084)
Gross profit	毛利	18,409	19,127
Other income, net	其他收入淨額	434	24
Selling and distribution costs	銷售及分銷成本	(7,757)	(6,917)
General and administrative expenses	行政及管理費用	(11,319)	(10,465)
Finance costs	財務成本	(711)	(433)
Share of profits and losses of:	應佔溢利及虧損：		
Joint venture	合營企業	2,606	(5,340)
Associate	聯營公司	1,043	1,113
PROFIT/(LOSS) BEFORE TAX	除稅前溢利／(虧損)	2,705	(2,891)
Income tax	所得稅	(424)	(1,049)
PROFIT/(LOSS) FOR THE PERIOD	期內溢利／(虧損)	2,281	(3,940)
Profit/(loss) attributable to:	溢利／(虧損)歸屬予：		
Shareholders of the Company	本公司股東	2,027	(4,984)
Non-controlling interests	非控制性權益	254	1,044
		2,281	(3,940)
		US cents 美仙	US cents 美仙
EARNINGS/(LOSSES) PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY	本公司股東應佔之每股 溢利／(虧損)		
		11	
Basic and diluted	基本及攤薄	0.80	(1.97)

**CONSOLIDATED STATEMENT OF
COMPREHENSIVE INCOME (CONTINUED)**
綜合全面收益表(續)

		Six months ended 30 June 截至六月三十日止六個月	
		2023 二零二三年 US\$'000 美元千元 (Unaudited) (未經審核)	2022 二零二二年 US\$'000 美元千元 (Unaudited) (未經審核)
PROFIT/(LOSS) FOR THE PERIOD	期內溢利／(虧損)	2,281	(3,940)
OTHER COMPREHENSIVE INCOME	其他全面收益		
Items that may be reclassified subsequently to profit or loss:	其後可能會重新分類至損益之項目：		
Exchange differences related to translation of foreign operations	與外地業務於換算時相關之匯兌差額	(4,110)	(4,214)
Share of other comprehensive income of:	應佔其他全面收益：		
Joint venture	合營企業	(5,298)	(6,144)
Associate	聯營公司	(873)	(1,126)
OTHER COMPREHENSIVE INCOME FOR THE PERIOD	期內其他全面收益	(10,281)	(11,484)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	期內全面收益總額	(8,000)	(15,424)
Total comprehensive income attributable to:	全面收益總額歸屬予：		
Shareholders of the Company	本公司股東	(7,063)	(15,199)
Non-controlling interests	非控制性權益	(937)	(225)
		(8,000)	(15,424)

**CONSOLIDATED STATEMENT OF
FINANCIAL POSITION**
綜合財務狀況表

			30 June 2023 二零二三年 六月三十日	31 December 2022 二零二二年 十二月三十一日
	Note 附註		US\$'000 美元千元 (Unaudited) (未經審核)	US\$'000 美元千元 (Audited) (經審核)
NON-CURRENT ASSETS		非流動資產		
Property, plant and equipment	12	物業、廠房及設備	89,791	93,847
Land lease prepayments		預付土地租賃費	4,839	5,168
Investments in joint venture		於合營企業的投資	99,430	102,122
Investments in associate		於聯營公司的投資	18,310	19,880
Other non-current assets		其他非流動資產	279	246
Total non-current assets		總非流動資產	212,649	221,263
CURRENT ASSETS		流動資產		
Inventories		存貨	37,059	45,734
Trade and bills receivables	13	應收貿易賬款及票據	44,912	40,863
Prepayments, deposits and other receivables		預付賬款、按金及 其他應收賬款	15,632	11,866
Cash and cash equivalents		現金及現金等價物	36,222	30,859
Total current assets		總流動資產	133,825	129,322
CURRENT LIABILITIES		流動負債		
Trade and bills payables	14	應付貿易賬款及票據	18,609	18,816
Other payables and accruals		其他應付賬款及預提費用	12,996	17,657
Bank borrowings		銀行借款	44,527	36,844
Income tax payables		應付所得稅	3,654	3,997
Total current liabilities		總流動負債	79,786	77,314
NET CURRENT ASSETS		淨流動資產	54,039	52,008
TOTAL ASSETS LESS CURRENT LIABILITIES		總資產減流動負債	266,688	273,271

**CONSOLIDATED STATEMENT OF
FINANCIAL POSITION (CONTINUED)**
綜合財務狀況表(續)

			30 June 2023 二零二三年 六月三十日	31 December 2022 二零二二年 十二月三十一日
		Note 附註	US\$'000 美元千元 (Unaudited) (未經審核)	US\$'000 美元千元 (Audited) (經審核)
NON-CURRENT LIABILITIES	非流動負債			
Bank borrowings	銀行借款		14,389	12,258
Other non-current liabilities	其他非流動負債		1,845	2,170
Deferred tax liabilities	遞延稅項負債		2,702	3,091
Total non-current liabilities	總非流動負債		18,936	17,519
NET ASSETS	資產淨值		247,752	255,752
EQUITY	權益			
Equity attributable to shareholders of the Company	本公司股東應佔權益			
Issued capital	已發行股本	15	25,333	25,333
Reserves	儲備		198,454	205,517
			223,787	230,850
Non-controlling interests	非控制性權益		23,965	24,902
TOTAL EQUITY	權益總額		247,752	255,752

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 綜合權益變動表

Six months ended 30 June 2023

截至二零二三年六月三十日止六個月

		Attributable to shareholders of the Company 本公司股東應佔						Non-	Total equity
		Issued capital 已發行股本	Capital reserve 資本儲備	PRC reserve funds 中國儲備基金	Exchange fluctuation reserve 外匯波動儲備	Retained profits 未分配利潤	Total	controlling interests 非控制性權益	Total equity
		US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元
		(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)
At 1 January 2023	於二零二三年一月一日	25,333	10,845	19,317	1,261	174,094	230,850	24,902	255,752
Profit for the period	期內溢利	-	-	-	-	2,027	2,027	254	2,281
Other comprehensive income for the period:	期內其他全面收益：								
Exchange differences related to translation of foreign operations	與外地業務於換算時相關之匯兌差額	-	-	-	(2,919)	-	(2,919)	(1,191)	(4,110)
Share of other comprehensive income of:	應佔其他全面收益：								
Joint venture	合營企業	-	-	-	(5,298)	-	(5,298)	-	(5,298)
Associate	聯營公司	-	-	-	(873)	-	(873)	-	(873)
Total comprehensive income for the period	期內全面收益總額	-	-	-	(9,090)	2,027	(7,063)	(937)	(8,000)
Transfer in/(out)	轉入/(出)	-	-	46	-	(46)	-	-	-
At 30 June 2023	於二零二三年六月三十日	25,333	10,845	19,363	(7,829)	176,075	223,787	23,965	247,752

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (CONTINUED) 綜合權益變動表(續)

Six months ended 30 June 2022

截至二零二二年六月三十日止六個月

		Attributable to shareholders of the Company 本公司股東應佔								
		Issued capital	Capital reserve	PRC reserve funds 中國	Exchange fluctuation reserve 外匯	Retained profits	Total	Non- controlling interests 非控制性 權益	Total equity	
		已發行股本 US\$'000 美元千元 (Unaudited) (未經審核)	資本儲備 US\$'000 美元千元 (Unaudited) (未經審核)	儲備基金 US\$'000 美元千元 (Unaudited) (未經審核)	波動儲備 US\$'000 美元千元 (Unaudited) (未經審核)	未分配利潤 US\$'000 美元千元 (Unaudited) (未經審核)	總額 US\$'000 美元千元 (Unaudited) (未經審核)	權益 US\$'000 美元千元 (Unaudited) (未經審核)	權益總額 US\$'000 美元千元 (Unaudited) (未經審核)	
At 1 January 2022	於二零二二年一月一日	25,333	10,845	17,989	16,793	182,099	253,059	30,464	283,523	
Loss for the period	期內虧損	-	-	-	-	(4,984)	(4,984)	1,044	(3,940)	
Other comprehensive income for the period:	期內其他全面收益：									
Exchange differences related to translation of foreign operations	與外地業務於換算時相關之 匯兌差額	-	-	-	(2,945)	-	(2,945)	(1,269)	(4,214)	
Share of other comprehensive income of:	應佔其他全面收益：									
Joint venture	合營企業	-	-	-	(6,144)	-	(6,144)	-	(6,144)	
Associate	聯營公司	-	-	-	(1,126)	-	(1,126)	-	(1,126)	
Total comprehensive income for the period	期內全面收益總額	-	-	-	(10,215)	(4,984)	(15,199)	(225)	(15,424)	
Dividend declared to non-controlling equity holders	宣派予非控制性權益股東 股息	-	-	-	-	-	-	(6,034)	(6,034)	
At 30 June 2022	於二零二二年六月三十日	25,333	10,845	17,989	6,578	177,115	237,860	24,205	262,065	

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS 簡明綜合現金流量表

		Six months ended 30 June 截至六月三十日止六個月	
		2023 二零二三年 US\$'000 美元千元 (Unaudited) (未經審核)	2022 二零二二年 US\$'000 美元千元 (Unaudited) (未經審核)
CASH FLOWS FROM OPERATING ACTIVITIES	經營活動之現金流量		
Cash (used in)/generated from operations	經營(所用)/產生之現金	(794)	3,037
Interest paid	已付利息	(1,396)	(1,018)
Income tax paid	已付所得稅	(962)	(82)
Net cash flows (used in)/generated from operating activities	經營活動(所用)/所得之現金流量淨額	(3,152)	1,937
CASH FLOWS FROM INVESTING ACTIVITIES	投資活動之現金流量		
Purchases of property, plant and equipment	購買物業、廠房及設備	(3,190)	(6,214)
Other cash flows arising from investing activities	其他源自投資活動之現金流量	534	(1,552)
Net cash flows used in investing activities	投資活動所用之現金流量淨額	(2,656)	(7,766)
CASH FLOWS FROM FINANCING ACTIVITIES	融資活動之現金流量		
Proceeds from bank borrowings	銀行借款所得款項	47,801	18,722
Repayment of bank borrowings	償還銀行借款	(35,889)	(15,208)
Net cash flows generated from financing activities	融資活動所得之現金流量淨額	11,912	3,514
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	現金及現金等價物增加/(減少)淨額	6,104	(2,315)
Cash and cash equivalents at beginning of period	期初之現金及現金等價物	30,859	31,093
Effect of foreign exchange rate changes, net	外匯率變動之影響淨額	(741)	(480)
CASH AND CASH EQUIVALENTS AT END OF PERIOD	期末之現金及現金等價物	36,222	28,298

NOTES TO INTERIM FINANCIAL REPORT**中期財務報告附註****1. GENERAL INFORMATION**

Chia Tai Enterprises International Limited (the “Company”) is a limited liability company incorporated in Bermuda. The Company and its subsidiaries hereinafter are collectively referred to as the “Group”. The Group is principally engaged in the manufacture and/or sale of chlortetracycline and other related products. Additionally, the Group is also involved, through its joint venture and associated company, in the trading of machinery and the manufacture and sale of automotive parts.

At 30 June 2023, the directors consider the immediate holding company of the Company to be Charoen Pokphand Foods Public Company Limited (“CPF”), which is incorporated in the Kingdom of Thailand and shares of which are listed on the Stock Exchange of Thailand, and remains to be as such as at the date of approval of these financial statements. CPF is a significantly owned company of Charoen Pokphand Group Company Limited (“CPG”), which is incorporated in the Kingdom of Thailand.

2. BASIS OF PREPARATION

This interim financial report is unaudited and has been prepared in accordance with International Accounting Standard (“IAS”) 34 *Interim Financial Reporting* issued by the International Accounting Standards Board (the “IASB”) and the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”).

The accounting policies and the basis of preparation adopted in the preparation of this interim financial report are consistent with those adopted in the annual financial statements for the year ended 31 December 2022, which were prepared in accordance with International Financial Reporting Standards (“IFRSs”) (which include all IFRSs, IASs and Interpretations) issued by the IASB, except for the accounting policy changes as set out in note 3 below. This interim financial report should be read in conjunction with the annual financial statements for the year ended 31 December 2022.

1. 一般資料

正大企業國際有限公司(「本公司」)為一家於百慕達註冊成立之有限公司。本公司及其附屬公司以下統稱為「本集團」。本集團主要從事製造及／或銷售金黴素及其他相關產品。此外，本集團亦透過其合營企業及聯營公司從事機械設備貿易及產銷汽車零部件。

於二零二三年六月三十日，董事認為，本公司之直接控股公司為於泰國註冊成立的Charoen Pokphand Foods Public Company Limited(「CPF」)，其股份於泰國證券交易所上市，並於截至本財務報告獲批當日仍然為本公司的直接控股公司。CPF為一家於泰國註冊成立的Charoen Pokphand Group Company Limited(「CPG」)重大持有之公司。

2. 編製基準

此中期財務報告乃未經審核及按照國際會計準則委員會頒佈之國際會計準則(「國際會計準則」)第34號*中期財務報告*及香港聯合交易所有限公司證券上市規則(「上市規則」)適用之有關披露規定而編製。

除載列於以下附註3之會計政策更改外，此中期財務報告之會計政策及編製基準與截至二零二二年十二月三十一日止年度之年度財務報表所採用之會計政策及編製基準一致，乃按照國際會計準則委員會頒佈之國際財務報告準則(「國際財務報告準則」)(亦包括所有國際財務報告準則、國際會計準則及詮釋)而編製。此中期財務報告應與截至二零二二年十二月三十一日止年度之年度財務報表一併閱讀。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

3. CHANGES IN ACCOUNTING POLICY AND DISCLOSURES

The IASB has issued a number of new standards, amendments to IFRSs and interpretation that are first effective for the current interim period. Of these, the following amendments may be relevant to the Group:

IFRS 7	IFRS 7, <i>Insurance contracts</i>
Amendments to IAS 1 and IFRS 2 Practice Statement 2	Amendments to IAS 1, and IFRS Practice Statement 2, <i>Making materiality judgements: Disclosure of accounting policies</i>
Amendments to IAS 8	Amendments to IAS 8, <i>Accounting policies, changes in accounting estimates and errors: Definition of accounting estimates</i>
Amendments to IAS 12	Amendments to IAS 12, <i>International Tax Reform – Pillar Two Model Rules (amendments)</i>

None of the new standard, amendment or interpretation have had a significant financial effect to the Group. The Group has not applied any new standard, amendment or interpretation that is not yet effective for the current period.

In June 2022, the Government of the Hong Kong Special Administrative Region of the People's Republic of China (the "Government") gazetted the Hong Kong Employment and Retirement Schemes Legislation (Offsetting Arrangement) (Amendment) Ordinance 2022 (the "Amendment Ordinance"), which will eventually abolish the statutory right of an employer to reduce its long service payment ("LSP") and severance payment payable to a Hong Kong employee by drawing on its mandatory contributions to the mandatory provident fund ("MPF") scheme (the "offsetting mechanism"). The Government has subsequently announced that the Amendment Ordinance will come into effect from 1 May 2025.

In July 2023, the Hong Kong Institute of Certified Public Accountants ("HKICPA") published "Accounting implications of the abolition of the MPF-LSP offsetting mechanism in Hong Kong" that provides guidance on the accounting considerations relating to the offsetting mechanism and the abolition of the mechanism. The Group has assessed the implications of this new guidance and is of the view that the related impact on the financial statements of the Group will not be significant.

3. 會計政策及披露之更改

國際會計準則委員會已頒佈若干國際財務報告準則的新準則、修訂及詮釋，並於本中期首次生效。下列為當中可能與本集團有關之修訂：

國際財務報告準則第17號	國際財務報告準則第17號 <i>保險合同</i>
國際會計準則第1號及國際財務報告準則實務聲明書第2號的修訂	修訂國際會計準則第1號及國際財務報告準則實務聲明書第2號作出重大判斷－會計準則披露
國際會計準則第8號的修訂	修訂國際會計準則第8號會計政策、會計估計變更及差錯－會計估計之定義
國際會計準則第12號的修訂	修訂國際會計準則第12號 <i>國際稅收改革之第二支柱模型規則 (修訂)</i>

採納國際財務報告準則的新準則、修訂及詮釋不會對本集團構成重大財務影響。本集團於本期內並無採納任何尚未生效的新準則、修訂或詮釋。

中華人民共和國香港特別行政區政府（「政府」）於二零二二年六月刊憲《二零二二年僱傭及退休計劃法例（抵銷安排）（修訂）條例》（「修訂條例」），最終廢除僱主可利用其向強制性公積金（「強積金」）計劃作出的強制性供款來減少其應付給香港僱員的長期服務金（「長期服務金」）和遣散費的權利（「對沖機制」）。政府其後宣布修訂條例將於二零二五年五月一日起生效。

香港會計師公會於二零二三年七月發布了《香港廢除強積金與長期服務金和遣散費的抵消機制的會計影響》，為與抵消機制和廢除該機制有關的會計考慮提供了指引。本集團已評估該新指引的影響，並認為對本集團財務報表的相關影響並不重大。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

4. OPERATING SEGMENT INFORMATION

For management purposes, the Group is organised into business units based on their products and services and has two reportable operating segments:

- the biochemical segment is principally engaged in the manufacture and/or sale of chlortetracycline and other related products; and
- the industrial segment is principally engaged in the trading of machinery and the manufacture and sale of automotive parts, through the Group's joint venture and associate.

Management monitors the results of the Group's operating segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on reportable segment profit, which is a measure of adjusted profit before tax. The adjusted profit before tax is measured consistently with the Group's profit before tax except that bank interest income, finance costs and items not specifically attributed to individual segments, such as head office or corporate administration expenses are excluded from such measurements.

Segment assets exclude unallocated corporate assets. Unallocated corporate assets include cash and cash equivalents, income tax receivable and other assets that are managed on a group basis.

Segment liabilities exclude unallocated corporate liabilities. Unallocated corporate liabilities include bank borrowings, income tax payables and deferred tax liabilities and other liabilities that are managed on a group basis.

All revenue from contracts with customers is recognised at the point in time when our customer obtains control of the promised goods, i.e. when products are delivered to the customers' premises for domestic sales or in accordance with the terms and conditions of sale for export sales. The major product line of the Group is the manufacture and/or sale of chlortetracycline and other related products in biochemical segment as disclosed in note 4(a).

Disaggregation of revenue from contracts with customers by geographical location of customers is disclosed in note 4(b)(i).

4. 經營分類資料

按管理所需，本集團將業務按產品及服務分成兩個可呈報經營分類：

- 生化分類代表主要製造及／或銷售金霉素及其他相關產品；及
- 工業分類代表主要從事機械設備貿易及產銷汽車零件（透過本集團之合營企業及聯營公司）。

管理層會獨立監察本集團經營分類之業績而作出資源分配之決定及評定其表現。分類表現評估乃根據可呈報分類之溢利，即以經調整稅前溢利計算。經調整稅前溢利之計算與本集團稅前溢利之計算一致，除銀行利息收入、財務成本及不屬於個別分類之項目，如總部或企業行政開支不包括在其計算當中。

分類資產不包括未分配企業資產。未分配企業資產包括現金及現金等價物、預付所得稅及其他在集團層面管理之資產。

分類負債不包括未分配企業負債。未分配企業負債包括銀行借款、應付所得稅、遞延稅項負債及其他在集團層面管理之負債。

所有源自與客戶的合約收入於客戶獲得承諾產品之控制權之時點確認，即於產品送達客戶場地時（國內銷售）或按照銷售條款和條件（出口銷售）。本集團主要的產品線為生化分類之製造及／或銷售金霉素及其他相關產品，如附註4(a)披露。

源自與客戶的合約收入按客戶所在地分類，並於附註4(b)(i)披露。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

4. OPERATING SEGMENT INFORMATION (CONTINUED)

4. 經營分類資料(續)

(a) Reportable operating segments

(a) 可呈報經營分類

The following tables present revenue, profit or loss and certain assets, liabilities and expenditure information for the Group's reportable operating segments during the period.

以下報表為本集團各可呈報經營分類於期內之收入、損益及若干資產、負債及開支資料。

Six months ended 30 June 2023

截至二零二三年六月三十日止六個月

		Biochemical operations 生化業務 US\$'000 美元千元 (Unaudited) (未經審核)	Industrial operations 工業業務 US\$'000 美元千元 (Unaudited) (未經審核)	Total 總額 US\$'000 美元千元 (Unaudited) (未經審核)
Segment revenue	分類收入			
Sales to external customers	銷售予外來客戶	82,810	-	82,810
Segment results	分類業績			
The Group	本集團	1,063	(801)	262
Share of profits and losses of:	應佔溢利及虧損：			
Joint venture	合營企業	-	2,606	2,606
Associate	聯營公司	-	1,043	1,043
		<u>1,063</u>	<u>2,848</u>	<u>3,911</u>
Reconciliation:	調節項目：			
Bank interest income	銀行利息收入			505
Finance cost	財務費用			(711)
Unallocated head office and corporate expenses	未分配總部及企業開支			(1,000)
Profit before tax	除稅前溢利			<u>2,705</u>
Other segment information	其他分類資料			
Depreciation and amortisation	折舊及攤銷	3,458	-	3,458
Capital expenditure*	資本開支*	3,190	-	3,190

* Including additions to property, plant and equipment.

* 包括物業、廠房及設備之新增。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

4. OPERATING SEGMENT INFORMATION (CONTINUED)

4. 經營分類資料(續)

(a) Reportable operating segments (Continued)

(a) 可呈報經營分類(續)

At 30 June 2023

於二零二三年六月三十日

		Biochemical operations 生化業務 US\$'000 美元千元 (Unaudited) (未經審核)	Industrial operations 工業業務 US\$'000 美元千元 (Unaudited) (未經審核)	Total 總額 US\$'000 美元千元 (Unaudited) (未經審核)
Segment assets	分類資產	186,400	123,751	310,151
Reconciliation: Unallocated corporate assets	調節項目： 未分配企業資產			36,323
Total assets	總資產			346,474
Segment liabilities	分類負債	32,372	15	32,387
Reconciliation: Unallocated corporate liabilities	調節項目： 未分配企業負債			66,335
Total liabilities	總負債			98,722
Other segment information	其他分類資料			
Investments in joint venture	於合營企業的投資	-	99,430	99,430
Investments in associate	於聯營公司的投資	-	18,310	18,310

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

4. OPERATING SEGMENT INFORMATION (CONTINUED)

4. 經營分類資料(續)

(a) Reportable operating segments (Continued)

(a) 可呈報經營分類(續)

Six months ended 30 June 2022

截至二零二二年六月三十日止六個月

		Biochemical operations 生化業務 US\$'000 美元千元 (Unaudited) (未經審核)	Industrial operations 工業業務 US\$'000 美元千元 (Unaudited) (未經審核)	Total 總額 US\$'000 美元千元 (Unaudited) (未經審核)
Segment revenue	分類收入			
Sales to external customers	銷售予外來客戶	81,211	–	81,211
Segment results	分類業績			
The Group	本集團	3,453	(804)	2,649
Share of profits and losses of:	應佔溢利及虧損：			
Joint venture	合營企業	–	(5,340)	(5,340)
Associate	聯營公司	–	1,113	1,113
		3,453	(5,031)	(1,578)
Reconciliation:	調節項目：			
Bank interest income	銀行利息收入			68
Finance cost	財務費用			(433)
Unallocated head office and corporate expenses	未分配總部及企業開支			(948)
Loss before tax	除稅前虧損			(2,891)
Other segment information	其他分類資料			
Depreciation and amortisation	折舊及攤銷	3,569	–	3,569
Capital expenditure*	資本開支*	6,800	–	6,800

* Including additions to property, plant and equipment.

* 包括物業、廠房及設備之新增。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

4. OPERATING SEGMENT INFORMATION (CONTINUED)

4. 經營分類資料(續)

(a) Reportable operating segments (Continued)

(a) 可呈報經營分類(續)

At 31 December 2022

於二零二二年十二月三十一日

		Biochemical operations 生化業務 US\$'000 美元千元 (Audited) (經審核)	Industrial operations 工業業務 US\$'000 美元千元 (Audited) (經審核)	Total 總額 US\$'000 美元千元 (Audited) (經審核)
Segment assets	分類資產	193,138	126,547	319,685
Reconciliation: Unallocated corporate assets	調節項目： 未分配企業資產			30,900
Total assets	總資產			350,585
Segment liabilities	分類負債	37,716	19	37,735
Reconciliation: Unallocated corporate liabilities	調節項目： 未分配企業負債			57,098
Total liabilities	總負債			94,833
Other segment information	其他分類資料			
Investments in joint venture	於合營企業的投資	–	102,122	102,122
Investments in associate	於聯營公司的投資	–	19,880	19,880

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

4. OPERATING SEGMENT INFORMATION (CONTINUED)

4. 經營分類資料(續)

(b) Geographical information

(b) 地區資料

(i) Revenue from external customers

(i) 來自外來客戶之收入

		Six months ended 30 June 截至六月三十日止六個月	
		2023 二零二三年 US\$'000 美元千元 (Unaudited) (未經審核)	2022 二零二二年 US\$'000 美元千元 (Unaudited) (未經審核)
Mainland China	中國大陸	45,094	32,905
Americas	美洲	15,916	19,720
Asia Pacific (excluding mainland China)	亞太地區(不包括中國大陸)	15,873	16,560
Elsewhere	其他地方	5,927	12,026
		82,810	81,211

The revenue information shown above is based on the location of customers.

上列收入資料乃按客戶所在地分類。

(ii) Non-current assets

(ii) 非流動資產

At 30 June 2023, 99% (31 December 2022: 99%) of the Group's non-current assets are located in mainland China.

於二零二三年六月三十日，本集團99% (二零二二年十二月三十一日：99%) 之非流動資產均位於中國大陸。

5. REVENUE

5. 收入

Revenue represents the aggregate of the invoiced value of goods sold, net of value-added tax and government surcharges, and after allowances for goods returned and trade discounts recognised within the scope of IFRS 15. All of the Group's revenue is from the biochemical segment.

收入指除增值稅及政府附加費，及扣除退貨及貿易折扣後之累積銷售發票淨額並在國際財務報告準則第15號的範圍內確認。所有集團之收入均來自生化業務。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

6. OTHER INCOME, NET

An analysis of other income, net is as follows:

		Six months ended 30 June 截至六月三十日止六個月	
		2023	2022
		二零二三年	二零二二年
		US\$'000	US\$'000
		美元千元	美元千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Bank interest income	銀行利息收入	505	68
Government grants	政府補助	227	644
Foreign exchange differences, net	外幣折算差異淨額	(801)	(916)
Others	其他	503	218
		434	24

6. 其他收入淨額

其他收入淨額分析如下：

7. FINANCE COSTS

		Six months ended 30 June 截至六月三十日止六個月	
		2023	2022
		二零二三年	二零二二年
		US\$'000	US\$'000
		美元千元	美元千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Interest expense on bank borrowings	銀行借款之利息費用	1,444	1,018
Less: interest expense capitalised*	減：利息費用資本化*	(733)	(585)
		711	433

7. 財務成本

* Interest expense was capitalised at interest rate based on the respective loan facilities of 3.3%-5.1% per annum (six months ended 30 June 2022: 3.5%-5.4%).

* 利息費用資本化乃按各貸款協議之年利率3.3%至5.1% (二零二二年六月三十日止六個月：3.5%至5.4%) 計算。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

8. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging:

		Six months ended 30 June 截至六月三十日止六個月	
		2023	2022
		二零二三年	二零二二年
		US\$'000	US\$'000
		美元千元	美元千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Cost of inventories sold	已出售存貨成本	64,401	62,084
Depreciation of property, plant and equipment	物業、廠房及設備之折舊	3,446	3,497
Amortisation of land lease prepayments	預付土地租賃費之攤銷	80	72

9. INCOME TAX

No provision for Hong Kong profits tax has been made for the period as the Group did not generate any assessable profits in Hong Kong during the current period (six months ended 30 June 2022: nil).

Subsidiaries operating in the People's Republic of China ("PRC") are subject to income tax at the rate of 25% (six months ended 30 June 2022: 25%) on their taxable income according to the PRC corporate income tax laws. In accordance with the relevant tax rules and regulations in the PRC, certain subsidiaries of the Group in the PRC enjoy income tax exemptions or reductions.

9. 所得稅

本集團於本期內未有在香港賺取任何應課稅收入，所以未於期內作香港利得稅撥備（截至二零二二年六月三十日止六個月：無）。

根據中國企業所得稅稅例，於中華人民共和國（「中國」）經營之附屬公司需就其應課稅收入按稅率25%（截至二零二二年六月三十日止六個月：25%）繳交所得稅。根據中國之相關稅務守則及法例，本集團於中國之若干附屬公司享有豁免或減收所得稅之優惠。

		Six months ended 30 June 截至六月三十日止六個月	
		2023	2022
		二零二三年	二零二二年
		US\$'000	US\$'000
		美元千元	美元千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Current – the PRC	本期 – 中國		
Charge for the period	期內支出	754	2,474
Under/(over)-provision in prior years	往年少/(多)計提	19	(183)
Deferred	遞延	(349)	(1,242)
Total tax expense for the period	期內稅項總支出	424	1,049

10. INTERIM DIVIDEND

The board has resolved not to declare an interim dividend for the six months ended 30 June 2023 (six months ended 30 June 2022: nil).

10. 中期股息

董事會決議截至二零二三年六月三十日止六個月不派付中期股息（截至二零二二年六月三十日止六個月：無）。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

11. EARNINGS/(LOSSES) PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY

The calculation of basic earnings/(losses) per share is based on the profit/(loss) for the period attributable to shareholders of the Company and the weighted average number of ordinary shares and convertible preference shares in issue during the period.

The calculation of basic earnings/(losses) per share is based on the following data:

Earnings/(losses)
Profit/(loss) for the period attributable to shareholders of the Company, used in the basic earnings/(losses) per share calculation

溢利
用於計算每股基本溢利/(虧損)之
本公司股東本期應佔溢利/(虧損)

2,027 (4,984)

Shares
Weighted average number of ordinary shares and convertible preference shares in issue during the period, used in the basic earnings/(losses) per share calculation

股份
用於計算每股基本溢利/(虧損)之
期內已發行之普通股及
可換股優先股加權平均數

253,329,087 253,329,087

As there were no potential dilutive ordinary shares during the six months ended 30 June 2023 and 2022, the amount of diluted earnings/(losses) per share is equal to basic earnings/(losses) per share.

11. 本公司股東應佔之每股溢利/(虧損)

每股基本溢利/(虧損)金額之計算乃根據本公司股東應佔期內溢利/(虧損)及期內已發行之普通股及可換股優先股加權平均數。

每股基本溢利/(虧損)乃根據以下數據計算：

Six months ended 30 June 截至六月三十日止六個月	
2023	2022
二零二三年	二零二二年
US\$'000	US\$'000
美元千元	美元千元
(Unaudited)	(Unaudited)
(未經審核)	(未經審核)

Six months ended 30 June 截至六月三十日止六個月	
2023	2022
二零二三年	二零二二年
(Unaudited)	(Unaudited)
(未經審核)	(未經審核)

於二零二三及二零二二年六月三十日止六個月期間並無潛在攤薄普通股，故每股攤薄溢利/(虧損)相等於每股基本溢利/(虧損)。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

12. PROPERTY, PLANT AND EQUIPMENT

12. 物業、廠房及設備

		2023 二零二三年 US\$'000 美元千元 (Unaudited) (未經審核)	2022 二零二二年 US\$'000 美元千元 (Audited) (經審核)
At 1 January:	於一月一日：		
Cost	成本	157,150	154,060
Accumulated depreciation and impairment	累計折舊及減值	(63,303)	(61,474)
Net carrying amount	賬面淨值	93,847	92,586
Net carrying amount :	賬面淨值：		
At 1 January	於一月一日	93,847	92,586
Additions	添置	3,190	15,771
Depreciation provided during the period/year	期內計提折舊	(3,377)	(6,786)
Disposals	出售	(40)	(110)
Exchange realignment	匯兌調整	(3,829)	(7,614)
At 30 June/31 December	於六月三十日／十二月三十一日	89,791	93,847
At 30 June/31 December:	於六月三十日／十二月三十一日：		
Cost	成本	153,234	157,150
Accumulated depreciation and impairment	累計折舊及減值	(63,443)	(63,303)
Net carrying amount	賬面淨值	89,791	93,847

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

13. TRADE AND BILLS RECEIVABLES

Depending on the requirements of the market and business, the Group may extend credit to its customers. The Group seeks to maintain strict control over its outstanding receivables. Overdue balances are reviewed regularly by management and interest may be charged by the Group for overdue trade receivable at rates determined by the Group with reference to market practice. In the opinion of the directors, there is no significant concentration of credit risk. An aging analysis of the Group's trade and bills receivables, based on the date of delivery of goods, is as follows:

		30 June 2023 二零二三年 六月三十日 US\$'000 美元千元 (Unaudited) (未經審核)	31 December 2022 二零二二年 十二月三十一日 US\$'000 美元千元 (Audited) (經審核)
60 days or below	60日或以下	21,000	18,117
61 to 180 days	61至180日	13,623	14,746
Over 180 days	多於180日	10,289	8,000
		44,912	40,863

14. TRADE AND BILLS PAYABLES

An aging analysis of the Group's trade and bills payables as at the end of the reporting period, based on the date of receipt of goods, is as follow:

		30 June 2023 二零二三年 六月三十日 US\$'000 美元千元 (Unaudited) (未經審核)	31 December 2022 二零二二年 十二月三十一日 US\$'000 美元千元 (Audited) (經審核)
60 days or below	60日或以下	15,903	15,535
61 to 180 days	61至180日	2,358	2,592
Over 180 days	多於180日	348	689
		18,609	18,816

13. 應收貿易賬款及票據

取決於市場及業務需求，本集團或給予客戶信貸期。本集團對結欠賬款採取嚴格之監控。管理層亦會定時檢查過期之結欠，及可能會按本集團參考市場慣例釐定之利率收取逾期利息。按董事意見，本集團沒有明顯集中信貸風險。本集團應收貿易賬款及票據之賬齡分析（以發貨日期為基準）如下：

14. 應付貿易賬款及票據

本集團於報告期末應付貿易賬款及票據之賬齡分析（以收貨日期為基準）如下：

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

15. SHARE CAPITAL

15. 股本

		30 June 2023 二零二三年 六月三十日 US\$'000 美元千元 (Unaudited) (未經審核)	31 December 2022 二零二二年 十二月三十一日 US\$'000 美元千元 (Audited) (經審核)
Authorised	法定		
<i>Ordinary shares:</i>	<i>普通股：</i>		
787,389,223 shares (31 December 2022: 787,389,223 shares) of US\$0.1 each	787,389,223股 (二零二二年十二月三十一日： 787,389,223股) 每股面值0.1美元	78,739	78,739
<i>Convertible preference shares:</i>	<i>可換股優先股：</i>		
12,610,777 shares (31 December 2022: 12,610,777 shares) of US\$0.1 each	12,610,777股 (二零二二年十二月三十一日： 12,610,777股) 每股面值0.1美元	1,261	1,261
		80,000	80,000
Issued and fully paid	已發行及繳足		
<i>Ordinary shares:</i>	<i>普通股：</i>		
240,718,310 shares (31 December 2022: 240,718,310 shares) of US\$0.1 each	240,718,310股 (二零二二年十二月三十一日： 240,718,310股) 每股面值0.1美元	24,072	24,072
<i>Convertible preference shares:</i>	<i>可換股優先股：</i>		
12,610,777 shares (31 December 2022: 12,610,777 shares) of US\$0.1 each	12,610,777股 (二零二二年十二月三十一日： 12,610,777股) 每股面值0.1美元	1,261	1,261
		25,333	25,333

There were no movements in the Company's issued ordinary shares and convertible preference shares during the six months ended 30 June 2023.

於截至二零二三年六月三十日止六個月內，本公司已發行普通股及可換股優先股概無變動。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

15. SHARE CAPITAL (CONTINUED)

Notes:

The convertible preference shares are convertible into ordinary shares of the Company and are entitled to the same dividends that are declared for the ordinary shares. Convertible preference shares do not carry the right to vote in shareholders' meeting. Upon winding up, the Company's residual assets and funds are distributed to the members of the Company in the following priority:

- (i) in paying to the holders of the convertible preference shares, pari passu as between themselves by reference to the aggregate nominal amounts of the convertible preference shares held by them respectively, an amount equal to the aggregate of the distribution value (as defined in the bye-laws of the Company) of all the convertible preference shares held by them respectively;
- (ii) the balance of such assets shall be distributed on a pari passu basis among the holders of any class of shares in the capital of the Company other than the convertible preference shares and other than any shares which are not entitled to participate in such assets, by reference to the aggregate nominal amounts paid up on the shares held by them respectively; and
- (iii) the remaining balance of such assets shall belong to and be distributed on a pari passu basis among the holders of any class of shares including the convertible preference shares, other than any shares not entitled to participate in such assets, by reference to the aggregate nominal amounts of shares held by them respectively.

The convertible preference shares shall be non-redeemable by the Company or the holders thereof.

16. CAPITAL COMMITMENTS

The Group had the following capital commitments as at the end of the reporting period:

Contracted, but not provided for:
Property, plant and machinery

已簽約，但尚未作出撥備：
物業、廠房及外機器

30 June

2023

二零二三年

六月三十日

US\$'000

美元千元

(Unaudited)

(未經審核)

31 December

2022

二零二二年

十二月三十一日

US\$'000

美元千元

(Audited)

(經審核)

8,406

9,213

15. 股本(續)

附註：

可換股優先股可轉換成本公司普通股及可收取與普通股持有人同等之股息。可換股優先股於股東會議不設投票權。於清盤時，本公司股東按以下次序分配本公司餘下資產及資金：

- (i) 向可換股優先股之持有人(彼等之間地位相等)參照彼等各自持有之可換股優先股面值總額支付相等於彼等各自持有之全部可換股優先股分派價值(於本公司細則中定義)總額之金額；
- (ii) 該等資產之結餘將按同等地位基準向本公司股本中任何類別股份(可換股優先股及無權參與分派該等資產之任何股份除外)之持有人(參照彼等各自持有之股份面值總額)予以分派；及
- (iii) 該等資產餘下之結餘將屬於並按同等地位基準向任何類別股份(包括可換股優先股但不包括無權參與分派該等資產之任何股份)之持有人(參照彼等各自持有之股份面值總額)予以分派。

本公司或持有人均不會對可換股優先股作出回購。

16. 資本承擔

本集團於報告期末之資本承擔如下：

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

17. RELATED PARTY TRANSACTIONS

17. 關連交易

(a) Transactions with related parties

(a) 與關連人士的交易

The Group had the following transactions with related parties during the period:

本集團於期內與關連人士有以下的交易：

	Six months ended 30 June		
	2023	2022	
	二零二三年	二零二二年	
	US\$'000	US\$'000	
	美元千元	美元千元	
	(Unaudited)	(Unaudited)	
	(未經審核)	(未經審核)	
Sales of goods to:			
C.P. Pokphand Co., Ltd. and its subsidiaries ("CPP Group")*	卜蜂國際有限公司及其附屬公司 (「卜蜂集團」)*	992	1,103
High Orient Enterprises Limited and its related entities, excluding CPP Group*	High Orient Enterprises Limited 及其關連企業，不包括卜蜂集團*	18,837	14,383
Other related entities with same shareholders as CPG	與CPG有相同股東 其之他關連企業	414	438

Note:

附註：

Prices of goods sold to related parties were determined with reference to the cost of raw materials, procurement costs, other value added, reasonable profit margins, market demand for goods and prices offered by independent third-party suppliers of similar products. The procedures to determine the prices of products sold to related parties are the same as those used to determine the prices of products supplied to independent third party customers. The selling prices to related parties shall be no more favourable than those made available to the Group's customers which are independent third parties.

向關連人士銷售的產品售價乃按原材料成本、採購成本、其他增值、合理的利潤率、市場對該產品之需求及由獨立第三方供應商提供類似產品的價格而釐定。釐定向關連人士銷售的產品售價的程式與釐定向獨立第三方客戶供應的產品售價所用者一致。向關連人士銷售的產品售價並不遜於本集團給予獨立第三方客戶之價格。

* These related party transactions also constituted continuing connected transactions as defined in Chapter 14A of the Listing Rules.

* 該等關連人士交易也構成上市規則第14A章內定義之持續關連交易。

(b) Outstanding balances with related parties

(b) 與關連人士之間未清賬

(i) Included in the Group's trade receivables as at 30 June 2023 were aggregate amounts of US\$21,703,000 (31 December 2022: US\$18,861,000) due from related companies, arising from transactions carried out in the ordinary course of business of the Group. The balances were unsecured, bore interest at rates determined by the Group after past due and were repayable within credit periods similar to those offered by the Group to its major independent third party customers.

(i) 本集團於二零二三年六月三十日之應收貿易賬款包括本集團經營日常業務交易時所產生的應收關連公司之款項合計為2,170.3萬美元(二零二二年十二月三十一日：1,886.1萬美元)。該等餘額乃無抵押、於過期後按本集團所定的利率計息及須於信貸期內償還(與本集團向主要獨立第三方客戶提供之利率及信貸期相若)。

(ii) Included in the Group's prepayments, deposits and other receivables as at 30 June 2023 were aggregate amounts of US\$5,990,000 (31 December 2022: US\$4,523,000) and US\$70,000 (31 December 2022: US\$20,000) due from associate and related companies respectively. The balances were unsecured, interest-free and with no fixed terms of repayment.

(ii) 本集團於二零二三年六月三十日之預付賬款、按金及其他應收賬款中，包含合計599.0萬美元(二零二二年十二月三十一日：452.3萬美元)及7.0萬美元(二零二二年十二月三十一日：2.0萬美元)分別為應收聯營公司及關連公司之款項。該餘額均無抵押、免息及無固定還款期。

OTHER INFORMATION

其他資料

INTERIM DIVIDEND

The Board has resolved not to declare an interim dividend for the six months ended 30 June 2023 (six months ended 30 June 2022: nil).

DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES OF THE COMPANY AND ITS ASSOCIATED CORPORATIONS

As at 30 June 2023, the interests and short positions of the directors and chief executives of the Company in the shares and underlying shares of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")) as recorded in the register required to be kept by the Company under Section 352 of the SFO, or as otherwise notified to the Company and The Stock Exchange of Hong Kong Limited (the "Stock Exchange") pursuant to Appendix 10 to the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules") – Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") are set out below:

Directors' interests in shares of the Company (Long Positions)

Name of director	Capacity	Number of ordinary shares held	Approximate percentage of the issued ordinary share capital of the Company
董事名稱	身分	所持普通股股份數目	估本公司已發行普通股股本概約百分比
Mr. Thirayut Phityaisarakul 李紹慶先生	Beneficial owner 實益擁有人	410,000	0.17%
Mr. Thanakorn Seriburi 李紹祝先生	Beneficial owner 實益擁有人	625,848	0.26%

Save as disclosed above, as at 30 June 2023, none of the directors or chief executives of the Company had any interests or short positions in the shares, underlying shares or debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) as recorded in the register required to be kept by the Company under Section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code.

中期股息

董事會決議截至二零二三年六月三十日止六個月不派付中期股息(截至二零二二年六月三十日止六個月:無)。

董事及主要行政人員持有本公司及其相聯法團的股份及相關股份的權益及淡倉

於二零二三年六月三十日,根據證券及期貨條例第352條規定由本公司備存之登記冊的記錄,又或根據香港聯合交易所有限公司(「聯交所」)證券上市規則(「上市規則」)附錄十之上市發行人董事進行證券交易的標準守則(「標準守則」)向本公司及聯交所發出的通知,各董事及主要行政人員持有本公司及其相聯法團的股份及相關股份的權益及淡倉(按證券及期貨條例第XV部所界定者)載列如下:

董事於本公司的權益(好倉)

除上述披露者外,於二零二三年六月三十日,根據證券及期貨條例第352條規定由本公司備存之登記冊的記錄,又或根據標準守則向本公司及聯交所發出的通知,概無任何本公司董事或主要行政人員在本公司或其相聯法團(按證券及期貨條例第XV部所界定者)的股份、相關股份或債權證中擁有任何權益或淡倉。

SUBSTANTIAL SHAREHOLDERS AND PERSONS WHO HAVE INTERESTS OR SHORT POSITIONS WHICH ARE DISCLOSEABLE UNDER THE SECURITIES AND FUTURES ORDINANCE

主要股東及根據證券及期貨條例規定須予披露擁有權益或淡倉的人士

As at 30 June 2023, the following persons (not being a director or chief executive of the Company) had the following interests or short positions in the shares and underlying shares of the Company as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO:

於二零二三年六月三十日，根據證券及期貨條例第336條規定由本公司備存之登記冊的記錄，下列人士（非本公司的董事或主要行政人員）於本公司的股份及相關股份擁有的權益或淡倉如下：

Name of shareholder	Notes	Capacity	Number of shares and underlying shares held	Approximate percentage of the issued ordinary share capital of the Company
股東名稱	附註	身分	持有股份及相關股份數目 (Note 1) (附註1)	佔本公司已發行普通股股本概約百分比 (Note 1) (附註1)
Charoen Pokphand Group Company Limited	(2)	Interest of controlled corporation 控制法團權益	127,748,147 (L)	53.07 (L)
Charoen Pokphand Foods Public Company Limited	(2)	Beneficial owner and interest of controlled corporation 實益擁有人及控制法團權益	127,748,147 (L)	53.07 (L)
CPF Investment Limited	(2)	Beneficial owner 實益擁有人	115,137,370 (L)	47.83 (L)
ITOCHU Corporation 伊藤忠商事株式會社		Beneficial owner 實益擁有人	60,179,593 (L)	25.00 (L)

Notes:

- The letter "L" denotes a long position.
- Charoen Pokphand Foods Public Company Limited ("CPF") held 127,748,147 shares and underlying shares of the Company, which included (i) 115,137,370 ordinary shares beneficially owned by CPF's wholly-owned subsidiary, CPF Investment Limited and (ii) 12,610,777 convertible preference shares beneficially owned by CPF. Charoen Pokphand Group Company Limited also declared interest in these shares by virtue of its shareholding interest in CPF.

Save as disclosed above, as at 30 June 2023, no persons (not being a director or chief executive of the Company) had any interests or short positions in the shares and underlying shares of the Company as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO.

附註：

- 「L」代表好倉。
- Charoen Pokphand Foods Public Company Limited (「CPF」) 持有127,748,147股本公司股份及相關股份，其中包括(i) CPF全資附屬公司CPF Investment Limited實益擁有的115,137,370股普通股及(ii) CPF實益擁有的12,610,777股可換股優先股。Charoen Pokphand Group Company Limited亦申報因擁有CPF的股權，故同樣擁有該等股份的權益。

除上述披露者外，於二零二三年六月三十日，根據證券及期貨條例第336條規定由本公司備存之登記冊的記錄，概無人士（非本公司董事或主要行政人員）在本公司的股份及相關股份中擁有任何權益或淡倉。

SHARE OPTION SCHEME

The Company adopted a share option scheme (the “Share Option Scheme”) on 18 March 2015. As at the date of this interim report, the total number of ordinary shares which may be issued upon exercise of all options to be granted under the Share Option Scheme shall not in aggregate exceed 24,071,831 shares, being 10% of the total number of ordinary shares of the Company in issue on the date of listing on 3 July 2015. As at the date of this interim report, no option had been granted, exercised, cancelled or lapsed under the Share Option Scheme.

CORPORATE GOVERNANCE CODE

The Company is committed to maintaining strict corporate governance standards. The principles of these standards are to uphold a high standard of ethics, transparency, accountability and integrity in all aspects of business and to ensure that affairs are conducted in accordance with applicable laws and regulations.

In the opinion of the Board, the Company has applied the principles and complied with the code provisions prescribed in the Corporate Governance Code as set out in Appendix 14 to the Listing Rules throughout the six months ended 30 June 2023.

DIRECTORS’ SECURITIES TRANSACTIONS

The Company has adopted the Code of Conduct for Securities Transactions, which is based on the required standard set out in the Model Code, as the code of conduct for dealings in the Company’s securities by its directors. All Directors responded to a specific enquiry by the Company and confirmed that they complied with the required standard set out in the Code of Conduct for Securities Transactions during the six months ended 30 June 2023.

REVIEW OF INTERIM REPORT

The interim financial report for the six months ended 30 June 2023 is unaudited, but has been reviewed by KPMG in accordance with Hong Kong Standard on Review Engagements 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the HKICPA. KPMG’s unmodified review report is set out on pages 6 to 7 of this interim report.

The audit committee of the Company has also reviewed the interim report for the six months ended 30 June 2023.

購股權計劃

本公司於二零一五年三月十八日採納購股權計劃（「購股權計劃」）。於本中期報告日期，根據購股權計劃將予授出的全部購股權獲行使時可予發行的普通股股份總數合共不得超過24,071,831股，相當於本公司於上市日期二零一五年七月三日已發行普通股股份總數的10%。於本中期報告日期，概無根據購股權計劃已授出、行使、註銷或失效的購股權。

企業管治守則

本公司致力保持嚴格的企業管治水平。其原則旨在維護公司在各業務方面均能貫徹高水平的道德、透明度、責任及誠信操守，並確保所有業務運作符合適用法律和法規。

董事會認為於二零二三年六月三十日止六個月內，本公司已應用載於上市規則附錄十四之企業管治守則的原則及遵守其守則條文。

董事的證券交易

本公司已採納證券交易行為守則，其乃根據標準守則所載的規定標準，作為其董事買賣本公司證券的行為守則。所有董事已回應本公司具體查詢並確認於截至二零二三年六月三十日止六個月內彼等遵守證券交易行為守則內所載的規定標準。

審閱中期報告

截至二零二三年六月三十日止六個月的中期財務報告為未經審核，但經畢馬威會計師事務所根據香港會計師公會頒佈的香港審閱工作準則第2410號獨立核數師對中期財務信息的審閱進行審閱。畢馬威會計師事務所的無修訂審閱報告已載於本中期報告的第6至7頁。

本公司審核委員會亦已審閱截至二零二三年六月三十日止六個月的中期報告。

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended 30 June 2023, neither the Company nor any of its subsidiaries have purchased, sold or redeemed any of the Company's listed securities.

By Order of the Board
Thanakorn Seriburi
Director

10 August 2023

購買、出售或贖回本公司的上市證券

截至二零二三年六月三十日止六個月內，本公司或其任何附屬公司概無購買、出售或贖回任何本公司的上市證券。

承董事會命
董事
李紹祝

二零二三年八月十日

CORPORATE INFORMATION

公司資料

Chairman and Non-executive Director

Mr. Soopakij Chearavanont

董事長及非執行董事

謝吉人先生

Executive Directors

Mr. Thirayut Phityaisarakul
(Chief Executive Officer (Biochemical Division))

Mr. Thanakorn Seriburi
(Chief Executive Officer (Industrial Division))

Mr. Nopadol Chiaravanont
Mr. Chawalit Na Muangtoun

執行董事

李紹慶先生
(行政總裁(生化業務))

李紹祝先生
(行政總裁(工業業務))

謝杰人先生
馬德壽先生

Non-executive Director

Mr. Yoichi Ikezoe

非執行董事

池添洋一先生

Independent Non-executive Directors

Mr. Surasak Rounroengrom
Mr. Cheng Yuk Wo
Mr. Edward Ko Ming Tung

獨立非執行董事

Surasak Rounroengrom先生
鄭毓和先生
高明東先生

Audit Committee

Mr. Cheng Yuk Wo (Chairman)
Mr. Surasak Rounroengrom
Mr. Edward Ko Ming Tung

審核委員會

鄭毓和先生(主席)
Surasak Rounroengrom先生
高明東先生

Remuneration Committee

Mr. Cheng Yuk Wo (Chairman)
Mr. Thanakorn Seriburi
Mr. Surasak Rounroengrom
Mr. Edward Ko Ming Tung

薪酬委員會

鄭毓和先生(主席)
李紹祝先生
Surasak Rounroengrom先生
高明東先生

Nomination Committee

Mr. Soopakij Chearavanont (Chairman)
Mr. Surasak Rounroengrom
Mr. Cheng Yuk Wo

提名委員會

謝吉人先生(主席)
Surasak Rounroengrom先生
鄭毓和先生

Corporate Governance Committee

Mr. Edward Ko Ming Tung (Chairman)
Mr. Nopadol Chiaravanont
Mr. Chawalit Na Muangtoun

企業管治委員會

高明東先生(主席)
謝杰人先生
馬德壽先生

Company Secretary

Mr. Lau Wing Yuen

公司秘書

劉永源先生

Registered Office

Victoria Place, 5th Floor
31 Victoria Street
Hamilton HM 10
Bermuda

註冊辦事處

Victoria Place, 5th Floor
31 Victoria Street
Hamilton HM 10
Bermuda

Principal Place of Business in Hong Kong

21st Floor, Far East Finance Centre
16 Harcourt Road, Hong Kong

香港主要營業地點

香港夏慤道16號
遠東金融中心21樓

Auditor

KPMG
Certified Public Accountants
Public Interest Entity Auditor
registered in accordance with
the Accounting and Financial Reporting Council Ordinance

核數師

畢馬威會計師事務所
執業會計師
於《會計及財務匯報局條例》下
的註冊公眾利益實體核數師

Principal Bankers

Bank of China
Bangkok Bank
China Construction Bank

主要往來銀行

中國銀行
盤谷銀行
中國建設銀行

Share Registrars

Bermuda Principal Share Registrar
Ocorian Management (Bermuda) Limited
Victoria Place, 5th Floor
31 Victoria Street
Hamilton HM 10
Bermuda

股份過戶登記處

百慕達主要股份過戶登記處
Ocorian Management (Bermuda) Limited
Victoria Place, 5th Floor
31 Victoria Street
Hamilton HM 10
Bermuda

Hong Kong Branch Share Registrar
Computershare Hong Kong Investor Services Limited
Shops 1712-1716, 17th Floor, Hopewell Centre
183 Queen's Road East, Wanchai, Hong Kong

香港股份過戶登記分處
香港中央證券登記有限公司
香港灣仔皇后大道東183號
合和中心17樓1712-1716號舖

Shares Listing

The Stock Exchange of Hong Kong Limited
Stock Code: 3839

股份上市地點

香港聯合交易所有限公司
股份代號：3839

Website

www.ctei.com.hk

網站

www.ctei.com.hk



CHIA TAI ENTERPRISES INTERNATIONAL LIMITED
正大企業國際有限公司

Incorporated in Bermuda with members' limited liability • Stock Code : 3839
於百慕達註冊成立之成員有限責任公司•股份代號: 3839